Macrogenics, Inc.

Amgen Fremont Inc.

Curagen Corporation

Dendreon Corporation

Celldex Therapeutics Limited

Francine Zhifen Chen

Leslie Sydnor Johnson

Paul A Moore

Ling Ling Huang

Deryk T Loo

Ian Nevin Foltz

Binyam Bezabeh

Ezio Bonvini

Peter S Mezes

Gregory M Landes

Kalpana Shah

Michael Jeffers

Jonathan C Li

Kam Fai Tse

Mehdi Mesri

Gary Starling

Nikolia Khramtsov

Chadwick Terence King

Xiao-Chi Jia

Bruce Alan Keyt

Jaspal Singh Kang

Edwin L Madison

Xiao Feng

Xiao-Dong Yang

Richard F Weber

Kathy Manchulenko

Jose R F Corvalan

Jennifer Hope Richardson

Peter Koon Bong Ling

Caroline Darne Scatena

Wayne R Godfrey

Stanislaw K Morkowski

Gadi Gazit

The present invention is directed to bi-specific monovalent diabodies that comprise two polypeptide chains and which possess at least one binding site specific for an epitope of CD3 and one binding site specific for an epitope of gpA33 (i.e., a 'gpA33&#xd7;CD3 bi-specific monovalent diabody'). The present invention also is directed to bi-specific monovalent diabodies that comprise an immunoglobulin Fc Domain ('bi-specific monovalent Fc diabodies') and are composed of three polypeptide chains and which possess at least one binding site specific for an epitope of gpA33 and one binding site specific for an epitope of CD3 (i.e., a &#x201c;gpA33&#xd7;CD3 bi-specific monovalent Fc diabody&#x201d;). The bi-specific monovalent diabodies and bi-specific monovalent Fc diabodies of the present invention are capable of simultaneous binding to gpA33 and CD3. The invention is directed to pharmaceutical compositions that contain such bi-specific monovalent diabodies or such bi-specific monovalent Fc diabodies. The invention is additionally directed to methods for the use of such diabodies in the treatment of cancer and other diseases and conditions.

Bi-specific monovalent diabodies that are capable of binding to gpA33 and CD3, and uses thereof

The present invention relates to antibodies that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Antibodies reactive with B7-H3 and users thereof

The present invention relates to antibodies and their fragments that are immunoreactive to the mammalian, and more particularly, the human B7-H3 receptor and to uses thereof, particularly in the treatment of cancer and inflammation. The invention thus particularly concerns humanized B7-H3-reactive antibodies and their immunoreactive fragments that are capable of mediating, and more preferably enhancing the activation of the immune system against cancer cells that are associated with a variety of human cancers.

Antibodies reactive with B7-H3, immunologically active fragments thereof and uses thereof

Antibodies reactive with B7-H3 and uses thereof

The invention described herein is related to antibodies directed to the antigen TIM-1 and uses of such antibodies. In particular, there are provided fully human monoclonal antibodies directed to the antigen TIM-1. Isolated polynucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions (FR's) and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies against T cell immunoglobulin domain and mucin domain 1 (TIM-1) antigen and uses thereof

Binding proteins, such as fully human monoclonal antibodies and fragments thereof, directed to the antigen Matriptase and uses of such binding proteins are disclosed. Nucleotide sequences encoding, and amino acid sequences comprising heavy and light chain immunoglobulin molecules capable of binding to Matriptase are also disclosed. The invention also discloses cell lines expressing such immunoglobulin molecules and monoclonal antibodies to Matriptase. The antibodies can be used to detect, prevent, and treat diseases such as cancer.

Binding proteins specific for human matriptase

The present invention is related to antibodies directed to the antigen PDGFD and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen PDGFD. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Antibodies directed to PDGFD and uses thereof

Growing community of inventors

San Francisco, CA, United States of America

Francine Zhifen Chen